

1 **Study protocol for a pilot clinical trial to understand neural mechanisms of response to a**
2 **psychological treatment for pain and anxiety in pediatric functional abdominal pain**
3 **disorders (FAPD)**

4 **Authors:** Natoshia R. Cunningham^{1,2*}, Michelle A. Adler^{1,2}, Brittany N. Barber Garcia^{2,3}, Taylor
5 Abounader⁴, Alaina K. Miller⁴, Mariela Monzalvo⁴, Ismaeel Hashemi⁵, Ryan Cox^{2,6}, Samantha
6 L. Ely⁷, Yong Zhou⁸, Mark DeLano^{8,9}, Todd Mulderink^{8,9}, Mathew J. Reeves¹⁰, James L.
7 Peugh^{11,12}, Susmita Kashikar-Zuck^{11,12}, Robert C. Coghill^{11,12}, Judith E. Arnetz^{1,2}, David C. Zhu⁹

8
9 ¹Department of Family Medicine, Michigan State University, Grand Rapids, Michigan, USA

10 ²College of Human Medicine, Michigan State University, Grand Rapids, Michigan State
11 University, Grand Rapids, Michigan, USA

12 ³Helen DeVos Children's Hospital Pediatric Behavioral Health, Grand Rapids, Michigan, USA

13 ⁴School of Professional Psychology, Wright State University, Dayton, Ohio, USA

14 ⁵Department of Pediatric Gastroenterology, Novant Health, North Carolina, USA

15 ⁶Helen DeVos Children's Hospital Pediatric Gastroenterology, Grand Rapids, Michigan, USA

16 ⁷Department of Psychiatry and Behavioral Neuroscience, Wayne State University, Detroit,
17 Michigan, USA

18 ⁸Corewell Health Radiology, Grand Rapids, Michigan, USA

19 ⁹Department of Radiology, College of Human Medicine, Michigan State University, Grand
20 Rapids, Michigan, USA

21 ¹⁰Department of Epidemiology and Biostatistics, Michigan State University, East Lansing,
22 Michigan, USA

23 ¹¹Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

24 ¹²Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital
25 Medical Center, Cincinnati, OH, USA.

26 *Corresponding author: natoshia@msu.edu

27 All authors had a substantive role in manuscript completion.

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Abstract

Background. Functional abdominal pain disorders (FAPD) are the most common chronic pain conditions of childhood and are made worse by co-occurring anxiety. Our research team found that the Aim to Decrease Pain and Anxiety Treatment (ADAPT), a six-session coping skills program using cognitive behavioral therapy strategies, was effective in improving pain-related symptoms and anxiety symptoms compared to standard care. In follow-up, this current randomized clinical trial (RCT) aims to test potential neural mechanisms underlying the effect of ADAPT. Specifically, this two-arm RCT will explore changes in amygdalar functional connectivity (primary outcome) following the ADAPT protocol during the water loading symptom provocation task (WL-SPT). Secondary (e.g., changes in regional cerebral blood flow via pulsed arterial spin labeling MRI) and exploratory (e.g., the association between the changes in functional connectivity and clinical symptoms) outcomes will also be investigated.

Methods. We will include patients ages 11 to 16 years presenting to outpatient pediatric gastroenterology care at a midwestern children’s hospital with a diagnosis of FAPD plus evidence of clinical anxiety based on a validated screening tool (the Generalized Anxiety Disorder-7 [GAD-7] measure). Eligible participants will undergo baseline neuroimaging involving the WL-SPT, and assessment of self-reported pain, anxiety, and additional symptoms, prior to being randomized to a six-week remotely delivered ADAPT program plus standard medical care or standard medical care alone (waitlist). Thereafter, subjects will complete a post assessment neuroimaging visit similar in nature to their first visit.

Conclusions. This small scale RCT aims to increase understanding of potential neural mechanisms of response to ADAPT. ClinicalTrials.gov registration: NCT03518216

51

Introduction

52 *1.1. Background*

53 Functional abdominal pain disorders (FAPD) are among the most common chronic pain
54 conditions impacting children and adolescents. These complex pain conditions are thought to
55 result from dysregulations in the brain-gut axis and are characterized by aberrant amygdalar
56 functional connectivity patterns when experiencing pain during a water loading symptom
57 provocation task (WL-SPT), and at rest when compared to healthy youth [1]. The prevalence of
58 such conditions ranges from 4% to 41% globally and the median rate is approximately 12% [2].
59 These conditions account for 50% of all pediatric gastroenterology (GI) visits [3]. One third of
60 youth with FAPD experience impairment over the long term (e.g., for five years or more) [4],
61 and impairment may be more pronounced in adolescent versus pre-adolescent youth [5].
62 Anxiety is also very common in youth with FAPD, with prevalence between 42% to 85% [5-7].
63 Youth with FAPD and comorbid anxiety have greater rates of pain-related impairment [8] and
64 higher pain intensity [5]. Those who have elevated levels of anxiety, pain and disability are at
65 risk for persistently elevated disability [8]. Further, youth with chronic pain conditions such as
66 FAPD and comorbid anxiety are less likely to respond to cognitive behavioral therapy for pain
67 management, the current gold standard for care [9].

68 To improve outcomes for youth impacted by FAPD and comorbid anxiety, the study PI
69 and her team developed an enhanced approach to care, called the Aim to Decrease Anxiety and
70 Pain Treatment (ADAPT) [10]. ADAPT is a six-session, individually delivered protocol that
71 targets pain and anxiety through a blend of live and web-based sessions drawn from cognitive
72 behavioral therapy [11, 12] and in the current study have also been infused with mindfulness
73 meditation approaches [13]. ADAPT was found to be superior in reducing symptoms of

74 functional disability and anxiety in youth with FAPD in a randomized clinical trial as compared
75 to standard medical treatment alone [14]. Although the study team has previously found
76 evidence of aberrant functional connectivity in the brains of youth with FAPD [1] (during the
77 WL-SPT and when compared to the brains of healthy youth), the potential neural correlates
78 underlying effective *treatments* for these conditions are unknown. This is important because it
79 allows us to understand whether an effective nonpharmacologic treatment for pain and anxiety
80 impacts neurological functioning in youth with FAPD. Here we report the protocol for a
81 randomized trial designed to investigate the potential neural mechanisms associated with the
82 treatment effect of ADAPT.

83 *1.2. Study aims and hypotheses*

84 The goal of this randomized controlled trial (RCT) is to investigate potential neural
85 mechanisms underlying the treatment effect of ADAPT. Specifically, it is hypothesized that
86 ADAPT will correspond to the normalization of hyperactive functional connectivity patterns
87 (following at WL-SPT and at rest) between the amygdala and other regions implicated in pain as
88 compared to those undergoing standard care/waitlist control condition. Secondly, we propose
89 that regional cerebral blood flow (CBF) observed via 3D Pulsed Arterial Spin Labeling (PASL)
90 MRI will be reduced following ADAPT versus standard care/waitlist (after the WL-SPT and at
91 rest). Lastly, reductions in functional connectivity and regional CBF will correspond to
92 reductions in child-reported pain intensity and unpleasantness symptoms. This paper details the
93 study protocol of this clinical trial, NCT03518216, funded by a National Center for
94 Complementary and Integrative Health/National Institutes of Health (NCCIH/NIH) K23 grant,
95 AT009458.

96 *Primary Outcomes. Aim 1a.* Left amygdala-prefrontal cortex (AMY-PFC) functional
97 connectivity will be significantly reduced (i.e., evidence of decreased hyperconnectivity) after
98 the WL-SPT post ADAPT vs. waitlist. *Aim 1b.* Changes between both the left and right
99 amygdala and other network regions (e.g., thalamus) that are implicated in pain processing (e.g.,
100 default mode network [1, 15-18]) following ADAPT versus waitlist will also be investigated via
101 a whole brain search. This includes changes following the WL-SPT and differences during rest
102 between the ADAPT and waitlist groups.

103 *Secondary Outcomes (Aim 2):* To assess if regional CBF reduction is associated with
104 cognitive (e.g., prefrontal cortex [PFC]), affective (e.g., pregenual anterior cingulate cortex
105 [pgACC], amygdala [AMY]), and visceral afferent (e.g., insula [INS], thalamus, anterior mid-
106 cingulate cortex [aMCC], S1 & S2) pain. It is hypothesized that regional CBF associated with
107 cognitive, affective, and visceral afferent pain will be significantly reduced (following the WL-
108 SPT and at rest) after ADAPT vs. waitlist.

109 *Exploratory Outcomes:* To assess if changes in functional connectivity and brain
110 activations following ADAPT will correspond to reductions in pain (intensity and
111 unpleasantness) and anxiety ratings. Our previous research has indicated amygdalar functional
112 connectivity changes in youth with FAPD undergoing water loading are evident when
113 accounting for changes in pain intensity and pain unpleasantness [1].

114 As noted below, additional measures of psychosocial factors (e.g., anxiety, pain
115 catastrophizing, adverse childhood experiences), physical impairment (e.g., functional disability,
116 pain interference) and sociodemographic data will also be collected.

117 **Methods**

118 *2.1. Study design and setting*

119 The current study is a masked and mechanistic pilot clinical trial. The primary study site
120 (Michigan State University [MSU], led by NRC) will coordinate the study activities. Any
121 modifications will be communicated with IRB, study team, data monitoring committee, and the
122 NCCIH as appropriate.

123 Study recruitment of male and female youth will take place in outpatient pediatric
124 gastroenterology clinics at Helen DeVos Children's Hospital/ (HDVCH)/Corewell Health. In-
125 person and virtual recruitment will be utilized depending on whether the patient presents to clinic
126 in person or virtually (see section 2.3 *Study Procedures* for more details). Patients diagnosed
127 with FAPD by the medical team who agree to participate will complete additional screening
128 measures to assess subject eligibility (see section 2.2. *Eligibility criteria* for more details).

129 Qualifying participants will complete two neuroimaging assessments with surveys
130 (baseline and post, approximately 8 weeks part) (see Fig 1) at an outpatient imaging clinic at a
131 satellite location of Corewell Health where the study scanner is located (approximately 15
132 minutes from the main children's hospital).

133 **Fig 1. Schedule of Enrollment, Interventions, and Assessments.** SPIRIT schedule of
134 participation.

135 Following the baseline assessment, participants will be randomized to ADAPT or waitlist
136 using a concealment method by a staff external to the study team (see section 2.4
137 *Randomization*). The outcome assessor, study PI and study statisticians will be blinded to
138 participant randomization. The blind will be broken at the clinical discretion of the supervising

139 psychologist (BBG). Circumstances for breaking the blind may include cases when a patient's
140 safety is at risk, differential attrition, or if a patient's symptoms remarkably worsen throughout
141 treatment. If the blind needed to be broken, the study team would communicate with the local
142 IRB, any NCCIH members involved in the study, and involve our study team, included but not
143 limited to the PI, co-mentors, the biostatistician, and the outcome assessors (post-baccalaureate
144 research coordinator).

145 The ADAPT program (see section 2.6 *Intervention* for more details) will be delivered
146 virtually by a trained psychological provider (advanced doctoral students of pediatric psychology
147 (TA, AM, MM)) under the supervision of a licensed clinical pediatric pain psychologist (BBG).
148 Of note, live portions of the original ADAPT protocol were originally delivered in-person,
149 however, due to COVID-19, we will deliver those portions of ADAPT using HIPAA compliant
150 Zoom videoconferencing.

151 The target population is male and female youth between the ages of 11-16 with functional
152 abdominal pain disorders (FAPD) and clinically significant anxiety based on the Generalized
153 Anxiety Disorder-7 [GAD-7] [19] measure with a total cut-off score ≥ 10 ; (see section 2.5.
154 *Assessments & Outcome Measures* for additional details). We aim to have between 17–25
155 participants in each arm for a total N of 34-50 participants in the study. Gender and age will be
156 used as blocking variables in randomization (see more details in section 2.4 *Randomization*).

157 We plan to approach approximately 124 participants, ages 11-16 years. Of those, we
158 expect 75% will agree to participate (n=93) based on our pilot functional magnetic resonance
159 imaging (fMRI) study [10]. Of those, we expect approximately 65% will qualify. Thus, we
160 anticipate recruiting n=60 to complete a baseline assessment. Based on our previous RCT, we
161 expect 85% of those recruited will complete the baseline assessment (n = 50) and the majority

162 will be retained in the study (90%, n=45). Based on our fMRI pilot study, we expect to lose
163 approximately 10% of participant data to movement artifacts yielding n=40 with usable data.

164 This study is approved by Michigan State University's institutional review board, (IRB),
165 STUDY00003419, with Helen DeVos Children's Hospital/Corewell Health relying on the
166 primary IRB.

167 *2.2. Eligibility criteria*

168 *Inclusion criteria* will include children who must: 1) be between 11 and 16 years of age
169 and their parent/primary caregiver will participate in the study; 2) meet criteria for FAPD based
170 on physician/nurse practitioner diagnosis of FAPD and ROME IV FAPD criteria [20, 21] (see
171 section 2.5. *Assessments & Outcome Measures* for additional details); 3) meet criteria for
172 presence of clinical anxiety (based on the Generalized Anxiety Disorder-7 [GAD-7] [19]
173 measure with a total cut-off score ≥ 10 ; (see section 2.5. *Assessments & Outcome Measures* for
174 additional details)) or a current diagnosis of an anxiety disorder as indicated in the patient
175 electronic medical record; 4) have sufficient English language ability (along with their caregiver)
176 necessary to complete the study measures and protocol.

177 *Exclusion criteria* will include patients with: 1) a significant medical condition(s) with an
178 identifiable organic cause including those that may include abdominal pain symptoms (e.g.,
179 Inflammatory Bowel Diseases); 2) a documented developmental delay(s), autism spectrum
180 disorder, a previously diagnosed thought disorder (i.e., psychosis), or bipolar disorder; 3)
181 significant visual, hearing, or speech impairment; organic brain injury; 4) current psychological
182 therapy for pain or anxiety; 5) depressive symptoms cut-off score ≥ 22 on the Patient Health
183 Questionnaire-9 [PHQ-9] [22] (see section 2.5. *Assessments & Outcome Measures* for additional

184 details), or current active suicidal ideation; 6) an implant such as a cochlear implant device, a
185 pacemaker or neurostimulator containing electrical circuitry or generating magnetic signals.
186 Participants with 7) any significant ferrous material in their body that could pose the potential for
187 harm in the MRI environment or cause signal dropout in key brain regions (i.e. orthodontia); 8)
188 reported current/suspected pregnancy; 9) evidence of claustrophobia; 10) inability or
189 unwillingness of individual or legal guardian/representative to give written informed consent.

190 *2.3. Study procedures*

191 Eligible participants with FAPD will be identified for the study from new or existing
192 patients seen at the outpatient pediatric GI clinics. The lead GI care provider (e.g., physician,
193 nurse practitioner) will confirm that identified patients meet criteria for FAPD, introduce the
194 study, and then study staff will speak with the family to provide additional details and obtain
195 verbal and written consent (caregiver) and assent (youth participant). If study staff are not
196 physically present (i.e., if the GI visit occurs via telehealth, or if study staff are unable to attend
197 the GI visit), virtual consent procedures will be conducted via phone and Research Electronic
198 Data Capture (REDCap) eConsent Framework to minimize patient risk (includes written
199 consent). Written consent will be obtained from the participating caregiver, and written assent
200 will be obtained from the participating child. After consent is obtained, study staff will conduct a
201 psychosocial screening to determine eligibility if screening was not performed as part of the
202 clinic visit (e.g., anxiety and depressive symptom screening); (see section 2.5. *Assessments &*
203 *Outcome Measures* and Fig 2 for additional details). Of note, the HDVCH/Corewell healthcare
204 system routinely screens patients for anxiety and depression using the PHQ-4 [23] as part of
205 standard medical care, with the GAD-7 [19] and PHQ-9 [22] subsequently administered for those
206 who endorse anxiety or depressive symptomatology. Even if children do not endorse symptoms

207 on the PHQ-4, the research team will administer the GAD-7 and PHQ-9 to interested and
208 potentially eligible participants following the consenting process.

209 **Fig 2. Referral, screening, and enrollment procedure.** The medical provider will confirm
210 patient diagnosis of FAPD and introduce the study. If a patient is interested, the research
211 assistant will follow-up with the patient and caregiver (in-person at the clinic visit or via phone).
212 The research assistant will perform consent procedures and complete screening measures that
213 were not a part of the patients' medical visit. After eligibility screening, the patient will be
214 enrolled.

215 Potentially eligible participants will also be screened for MRI eligibility (e.g., to rule out
216 claustrophobia and presence of metal in the body). Enrolled patients will then be scheduled for
217 their MRI visits, approximately 8 weeks apart (see Fig 3). For participating, youth will receive
218 up to \$200 in Amazon gift cards (\$100 at baseline and \$100 at the post assessment). If a
219 participant elects not to complete ADAPT, they are still eligible to complete the post-assessment.

220 **Fig 3. Study timeline.** Participants will be screened and if eligible, will be scheduled for a
221 baseline assessment. Following the baseline visit, participants will be randomized to either
222 ADAPT or a waitlist control group. Participants will complete a post assessment ~7-9 weeks
223 from the baseline assessment. Participants who are part of the waitlist control group will be
224 offered ADAPT following their post assessment as a clinical courtesy, which is detailed in the
225 consent process.

226 *2.4. Randomization*

227 Following the baseline visit, MRI images will be reviewed by a radiologist (TM, MD) for safety.
228 Assuming no incidental findings which would preclude participation are present, participants

229 will be randomized. Randomization will be generated using PROC PLAN in SAS 9.3 by an
230 external team member. Gender and age will be used as blocking variables in randomization. The
231 randomizer will not have access to the data. The randomization schedule and code sheet will be
232 held confidentially by a designated secondary research team member not involved in data
233 collection, and the study interventionist will contact the designee to get the next assignment
234 when a participant is enrolled in the study. The outcome assessor, study PI, and study statistician
235 will be blinded to participant randomization. Patients and their families will be informed of
236 group assignment within one week of their baseline assessment and begin ADAPT or waitlist
237 approximately one week after group assignment.

238 *2.5. Assessments & Outcome Measures*

239 As noted above, qualifying participants and their respective caregivers will be invited to
240 attend an in-person baseline assessment with neuroimaging. Neuroimaging sequences will be
241 used to assess the primary and secondary outcomes. Participants will complete some additional
242 study measures (see below). Caregivers will complete several measures pertaining to their
243 child's pain and child's worries in addition to a measure of their own psychological symptoms.
244 To minimize burden, participants and caregivers will be given the option to either complete the
245 majority of measures up to 5 days before this visit using their own electronic device (to reduce
246 the length of the in-person visit; see details below).

247 Psychometrically validated instruments (self-report unless otherwise indicated) sensitive
248 to change in pediatric health studies will be used. All assessments will be delivered directly to
249 participants and caregivers and collected via autonomous self-report in REDCap, either during
250 the in-person neuroimaging study visits or 1-5 days beforehand. The research coordinator will

251 oversee data collection to ensure data is complete and collected in a timely manner. The study
252 coordinator performing outcome assessments will be blinded to group assignment.

253 During the neuroimaging portion of the assessment, participants will use a sliding scale to
254 report their current pain intensity, pain unpleasantness, and anxiety. Specifically, participants
255 will enter the MRI scanner, where scans of brain structures and cerebral blood flow will be
256 performed while participants provide current pain and anxiety ratings (~25 minutes). Participants
257 will then exit the scanner to undergo the WL-SPT, a validated, non-invasive procedure for youth
258 ages 8-16 to create visceral pain sensations which has been previously used by the research team
259 to understand neural mechanisms of FAPD pain [1].

260 Participants will ingest water until they have achieved complete fullness eliciting
261 discomfort (~5 minutes). Immediately following the WL-SPT, participants will rate their current
262 pain and anxiety. Then, participants will re-enter the scanner and repeat a similar series of scans
263 (~20 minutes) with current pain and anxiety ratings. At the completion of all scans, participants
264 will rate their current pain and anxiety once more. Post-assessment measures will follow these
265 same procedures.

266 *2.5.1. Primary Outcomes (collected at pre and post assessments).* Blood oxygenation level
267 dependent (BOLD) resting-state fMRI (rs-fMRI) will be used to assess functional connectivity
268 between the left and right amygdala and brain regions implicated in the FAPD pain experience
269 [1, 15-18] prior to and following WL-SPT, in those undergoing ADAPT versus waitlist.

270 *2.5.2. Secondary Outcomes (collected at pre and post assessments).* Similarly, the potential
271 regional cerebral blood flow (CBF) prior to and following WL-SPT, in the ADAPT group versus
272 waitlist will be assessed with the 3D PASL MRI perfusion technique.

273 2.5.3. *Exploratory Outcomes (collected at pre and post assessments)*. We will explore if
274 changes in functional connectivity (BOLD) and regional CBF following ADAPT will correspond
275 to reductions in pain (intensity and unpleasantness) and anxiety ratings. We will also explore the
276 effect of pain on the connectivity of all 17 brain networks as defined by Yeo et al. [24].

277 **Magnetic Resonance Imaging (MRI)**: MRI data will be acquired on a Siemens Prisma
278 3T scanner with a 64-channel head/neck coil. Image quality using this scanner has been certified
279 by an MRI physicist (DZ and YZ) based on both human brain and phantom scans. The following
280 three sequences will be used in this study:

281 (1) 3D T1-weighted Magnetization-Prepared-Rapid-Acquisition-of-Gradient-Echo (3D
282 MPRAGE) sequence (5 min 12 sec) will be used to visualize anatomical regions and
283 to isolate regions of interest for the analyses of functional connectivity and CBF.
284 Acquisition parameters: voxel size = $1 \times 1 \times 1$ mm³, field of view (FOV) = 256×256
285 mm², 208 sagittal slices, time of repetition (TR) = 2300 ms, time of echo (TE) = 2.98
286 ms, time of inversion (TI) = 900 ms, flip angle (FA) = 9°, and parallel imaging
287 acceleration factor = 2. Brain parcellation, regional and whole-brain volume
288 calculation will be performed using FreeSurfer [25]. The accuracy of the procedures
289 will be confirmed by visual inspection.

290 (2) rs-fMRI (12 min 2 sec) will be used to assess functional connectivity. In a dim-light
291 environment, a 12-minute rs-fMRI scan will be acquired while the subjects are asked
292 to relax and have their eyes closed [26]. An eye-closed condition will likely be easier
293 to maintain for our subjects [27, 28]. Acquisition parameters: Isotropic voxel size of
294 $2.5 \times 2.5 \times 2.5$ mm³, 60 contiguous axial slices, FOV = 22 cm \times 22 cm, TE = 30 ms,
295 TR = 1100 ms, FA = 63°, 4 dummy time points discarded, 650 time points, and

296 simultaneous multislice acceleration factor = 4. Data will be analyzed using AFNI
297 [29]. Slice-timing and motion corrections will be applied. Seed-based functional
298 connectivity to the left/right amygdala will be analyzed based on the correlation
299 between the mean time-course at the left/right amygdala and other voxels in the rest
300 of the brain. Similar seed-based connectivity analyses can be carried to other brain
301 regions.

302 In addition to examining functional connectivity to the amygdala, we will also
303 calculate the network connectivity of the 17 functional networks defined in the atlas
304 developed by Yeo et al. [24], which is based on rs-fMRI datasets from 1,000 healthy
305 young adults as part of our exploratory analysis. Since pain is a heterogenous
306 experience with multiple networks involved, we will explore these 17 networks
307 broadly and also anticipate specific patterns of change emerging for the default mode
308 network [1] defined in this atlas.

309 (3) 3D Pulse Arterial Spin Labeling (3D PASL) sequence at a perfusion mode of FAIR
310 QII (5 min 24 sec) will be used to measure regional CBF [30, 31]. Acquisition
311 parameters: 3D acquisition with FOV = 240 × 240 mm², matrix size = 64 × 64, 32
312 4.5-mm axial slices, TR = 4000 ms, TE = 20.26 ms, bolus duration = 800 ms,
313 inversion time = 2000 ms, 10 control-label pairs of images acquired and averaged to
314 improve signal/noise ratio, and fat saturation. The relative CBF maps will be
315 generated based on the relatively difference of the control and label images.

316
317 The 3D MPRAGE images will be collected at the beginning of the scan. To assess the
318 effect of WL-SPT on functional connectivity and CBF, the rs-fMRI and ASL images will

319 be collected before and after the WL-SPT (Fig 4). Participants are instructed not to
320 consume food or water within one hour prior to the MRI scan. Total MRI scanning time
321 is approximately 45 minutes per session to minimize participant burden.

322 **Fig 4. MRI Procedure.** The timing scheme of pain and anxiety ratings, MRI and WL-
323 SPT.

324 *2.5.3. Exploratory Outcomes (collected at pre and post assessments)*

325 **Pain Intensity and Unpleasantness Visual Analog Scales (VAS)** [32, 33]. Pain
326 intensity is associated with nociceptive processing and is a common measure of treatment
327 response [34]. Pain unpleasantness is related to affective network activity and is highly
328 responsive to meditation [35]. These will be collected using a physical sliding scale
329 during neuroimaging.

330 **State Anxiety (VAS)** [36]. 0-10 self-report of how anxious the child is feeling in the
331 present moment. This will be collected with a physical sliding scale during
332 neuroimaging.

333 *2.5.4. Other Related Measures (collected at pre and post assessments unless otherwise specified)*

334 **Fullness Rating Scale** [37]. Youth will be asked to indicate how full they felt after water
335 ingestion by selecting from images representing different levels of fullness, from empty
336 (coded 0) to full (coded 4). This will be collected in person during neuroimaging.

337 **Edinburgh Handedness Inventory** [38]. A validated measure that assesses the
338 dominance of a person's right or left hand in everyday activities. Given our pediatric
339 sample, one original item was removed (striking a match).

340 **Menstruation Query.** Female participants who have reached menarche will be asked if
341 they are currently menstruating and if so, how much pain is associated (using a visual
342 sliding scale). During screening, participants will be asked if they have achieved
343 menarche. If participants indicate that they have, we will query the date of their last
344 menstrual cycle.

345 **Peterson Pubertal Developmental Scale (PDS)** [39]. A valid and reliable pubertal status
346 assessed via clinician interview.

347 **Concomitant Medication Form.** Concomitant medication information (medication
348 name, reason for taking, unit, frequency, route, etc.) and therapies will be obtained via
349 chart review prior to the baseline visit. Study staff will confirm with caregivers that the
350 information is correct and up to date at the baseline and post assessment visits. Any
351 changes in medication from baseline to post assessment will be documented.

352 *2.5.5. Participant Characteristics and Demographic Factors (collected at pre and post*
353 *assessments unless otherwise indicated)*

354 **Child Pain History & Sociodemographic Factors.** Demographic factors, school
355 absences, pain duration, location, concomitant psychological treatments, and insurance
356 type. Birth date, sex, gender, race, and ethnicity of participant will also be collected.

357 **Primary Care Provider.** The name of participant's primary care provider and the name
358 of their practice, along with contact information will be collected at the pre assessment.

359 *2.5.6. Screening Measures (collected at screening, prior to study enrollment)*

360 **Rome IV FAPD Diagnosis Checklist** [21] (medical provider report). FAPD criteria
361 based on the Rome IV criteria [21]. FAPD includes irritable bowel syndrome (IBS),
362 functional dyspepsia, abdominal migraine, and FAPD- not otherwise specified. To meet
363 the criteria for FAPD, a child must endorse continuous or episodic pain at least 4 times in
364 a month that does not exclusively occur during a physiological event (e.g., eating,
365 menses) for a period of 2 months or longer, and that cannot be fully explained by another
366 medical condition after appropriate evaluation. This questionnaire will allow us to group
367 our samples into specific diagnostic subtypes of FAPD.

368 **Generalized Anxiety Disorders-7, GAD-7** [19]. A seven-item measure assessing for
369 generalized anxiety symptoms in the last two-weeks. The measure has a cut-off score for
370 moderate anxiety ≥ 10 . This measure has been validated for use in pediatric populations
371 [40]. This measure is also collected at the post assessment.

372 **Patient Health Questionnaire-9** [22]. A validated and reliable measure of depressive
373 symptoms in the past 2 weeks. Categories of severity are as follows: 0-4: Minimal
374 Depression, 5-9: Mild Depression, 10-14: Moderate Depression, 15-19: Moderately
375 Severe Depression, 20-27: Severe Depression. This measure is also collected at the post
376 assessment. Those endorsing thoughts of death on this measure will undergo a
377 comprehensive safety assessment to rule out active suicidal ideation. Youth will be
378 excluded from participating in the study (and referred for additional care) if they report
379 current active suicidal ideation or if their score is 22 or higher.

380 **MRI Safety and Screening.** Research staff will screen for MRI contraindications to
381 determine if participant can safely complete MRI protocol.

382 **Claustrophobia Screening.** Research staff will screen for signs of claustrophobia to
383 determine if the participant is claustrophobic. A brief interview to further assess for a fear
384 of enclosed spaces will be administered. This interview was adapted from a portion of the
385 Anxiety Disorder Interview Schedule-Child Report [41], a validated, semi structured
386 diagnostic interview to assess for the presence of child psychological disorders.
387 Responses on this module will help to determine eligibility for the study and will be used
388 in an attempt to reduce instances of unanticipated participant anxiety during the
389 neuroimaging scan. This process has been effective in our pilot neuroimaging research
390 [1] with this population as we did not lose a single participant due to scanner-related
391 anxiety.

392 2.5.7. *Pain Related Measures (collected at pre and post assessments)*

393 **Visual Analog Scale (VAS) [32] for pain.** Participants will report their average, highest,
394 and lowest pain levels in the past two weeks. If the electronic or physical VAS slider
395 cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be
396 used. Parents will also provide an assessment of their child’s pain in the past two weeks.

397 **Other Pain Locations.** Participants will be queried about other pain sources besides
398 abdominal pain.

399 2.5.8. *Functional Disability Related Outcomes (collected at pre and post assessments)*

400 **Functional Disability Inventory (FDI) [42].** A 15-item measure of physical/daily
401 function in last few days. This measure has been validated in pediatric chronic pain [43]
402 and used in pediatric FAPD samples [5, 9]. Child and parent versions will be obtained.

403 **NIH PROMIS Pain Related Disability Pain Interference Scale**[44]. A validated
404 measure of functional impairment due to pediatric pain in the past 7 days.

405 *2.5.9. Mental Health Related Measures (collected at pre and post assessments)*

406 **Screen for Child Anxiety Related Disorders, SCARED** [45]. Child anxiety (reported
407 by child and parent) in the past 3 months; ≥ 25 is indicative of clinical anxiety. This
408 measure has been recommended for use by the American Academy of Pediatrics [46] and
409 has been validated in pediatric chronic pain [45, 47, 48] and used in pediatric FAPD
410 samples [5, 9].

411 **Child COVID-19 Related Distress**. A child-reported item assessing the child's distress
412 in relation to the COVID-19 pandemic on a sliding scale from 0-10, with anchors labeled
413 "no distress" and "extreme distress". This measure was added prior to launching the
414 study and following the COVID-19 pandemic.

415 **COVID-19 Exposure and Family Impact Survey (CEFIS)** [49]. A measure from the
416 Center for Pediatric Traumatic Stress to capture the impact of the COVID-19 pandemic
417 on families and caregivers. This measure was added following the COVID-19 pandemic,
418 which occurred prior to launching the study.

419 **Self-Efficacy Pain Scale- Child Version** [50]. A validated and reliable 7-item measure
420 of child self-efficacy (reported by both child and parent) when in pain.

421 **Affective Reactivity Index (ARI)- Self- Report** . A validated 7-item measure of child
422 irritability in the last 7 days. Participants will complete this measure as self-report, and
423 caregivers will provide their report of the child.

424 **Pain Catastrophizing Scale for Children** [51]. A validated 13-item measure of
425 maladaptive beliefs about pain and feelings experienced when in pain. Participants will
426 complete this measure as self-report, and caregivers will provide their report of the child.

427 **Depression Anxiety Stress Scales** [52]. A validated and reliable measure with 21 items
428 completed by the caregiver of assessing for self-reported caregiver depression, anxiety,
429 and tension/stress.

430 **Adverse Childhood Experiences (ACEs)** [53]. A valid, 9-item measure used by the
431 National Survey of Children's Health that assesses for adverse events occurring in
432 childhood before the age of 18.

433 *2.5.10. Concomitant Care.*

434 Any concomitant interventions (i.e., medical, and psychological) experienced by the
435 participants (either allowed (e.g., pharmacological treatments for FAPD) or prohibited
436 (psychological therapy for anxiety or pain), see section 2.2 *Eligibility Criteria*) will also be
437 recorded at baseline and post assessments. Participants will provide the reason and duration of
438 concomitant interventions at the baseline and post assessment visits.

439 *2.5.10. Adverse Event Queries.*

440 Participants will be queried about any experienced adverse events during their second
441 session of ADAPT (if randomized to ADAPT treatment group). This form will also be
442 administered at post assessment. For those randomized to waitlist, they will complete this form
443 at post assessment, and then at ADAPT sessions 2 and 6 (if they opt to complete ADAPT).

444 **Adverse Event Query Form.** A form to be completed via clinician or research
445 coordinator interview assessing for adverse events experienced by participants.

446 2.6. *Intervention*

447 2.6.1. *The Aim to Decrease Anxiety and Pain Treatment (ADAPT).*

448 ADAPT is a psychological intervention that, in the current investigation, integrates
449 mindfulness meditation with cognitive behavioral therapy approaches for managing pain and
450 anxiety to improve patient outcomes (see Table 1). ADAPT was originally developed from a
451 CBT protocol for pain management [12] and from the “Cool Kids” program for anxiety [11]. The
452 current iteration integrates mindfulness meditation strategies from an established protocol [13].
453 ADAPT is primarily a child-focused, individual therapy with some caregiver involvement. The
454 duration of ADAPT is 6 six weeks, although up to eight weeks will be permitted to account for
455 scheduling conflicts and participant illness. In the current study, there will be two live
456 videoconference (Zoom) sessions with an interventionist (60 minutes) once per week for the first
457 two weeks, followed by 4 weeks of self-paced web modules (30 minutes per week) in
458 conjunction with interventionist support (15-30 minutes per week). Prior to the study launch (as
459 a result of the COVID-19 pandemic), ADAPT was revised to be delivered fully remotely (e.g.,
460 live, in-person sessions to be delivered via videoconferencing). In the event of technical
461 difficulties, live sessions can also be completed over phone calls. Preliminary testing has shown
462 that ADAPT is feasible and successfully reduces pain-related disability and anxiety over time [9,
463 14]. The interaction with the interventionist has been shown to be a key component engaging
464 youth in the program [54], and ADAPT has shown to be associated with improvements in
465 caregiver anxiety [55]. All participants will receive or be offered ADAPT, either immediately

466 following baseline assessment and randomization, or after completing the post assessment if

Table 1. ADAPT Protocol

Session	Attendee(s)	Format	Content
1	Participant, caregiver	Live via zoom	Introduction Gate control theory of pain Anxiety education* Deep/mindful breathing Guided Imagery
2	Participant (with caregiver review)	Live via zoom	Progressive muscle relaxation Calming statements Activity Pacing
3	Participant, caregiver	Web-based with Zoom	Please activity scheduling Problem solving
4	Participant, caregiver	Web-based with Zoom	Thinking like a detective* Identifying and challenging automatic thoughts
5	Participant, caregiver	Web-based with Zoom	Fighting fears by facing fears* Building social skills: assertiveness*
6	Participant, caregiver	Web-based with Zoom	Maintenance planning

467 participants are randomized to waitlist.

468 Note. Live sessions occur via HIPPA-compliant Zoom videoconferencing (1 hour). Web-based
469 sessions with zoom are self-paced modules (approximately 30 minutes) and therapist support
470 (approximately 15-30 minutes). All participants are permitted to continue their medical care as
471 usual throughout the duration of the study. *Drawn from anxiety-specific treatment protocol,
472 “Cool Kids” [11]. The remaining content is adapted from a pain coping skills program [12] or a
473 mindfulness meditation protocol [13].

474 *2.6.2 Treatment integrity*

475 All sessions will be video recorded (with patient permission) and stored. Treatment
476 integrity will be assessed using video recordings of videoconference sessions by independent
477 evaluators (e.g., doctoral students or medical trainees). Integrity scores (0–100%) used in prior
478 research [12, 14] will be obtained. Items assessed included delivery of session-specific skills and
479 assessment of participant comprehension. There will also be regular supervision of the
480 interventionist with a licensed psychology to review protocol and insure treatment fidelity.

481 *2.6.3 Waitlist group*

482 Participants in the waitlist arm will follow their gastroenterologists’ recommendations for
483 FAPD management. Waitlist participants will not be permitted to receive psychological care for
484 pain or anxiety outside of the study during their participation in order to minimize possible
485 similar treatment effect on waitlist control group, and will be offered ADAPT following their
486 post assessment as a courtesy.

487 *2.7. Data Management and Monitoring*

488 An external data monitoring committee comprising of 3 external MSU faculty with
489 specialties in bio-behavioral statistics, global neuropsychiatry, and neuroscience will meet

490 quarterly to assess study progress. The NCCIH will provide oversight via yearly study site visits
491 through Westat.

492 To ensure confidentiality, identification numbers will be used in lieu of names and data
493 will be kept in locked files in the PI's research location or on a secure computer that is
494 designated specifically for the purposes of this project. All data (except for MRI data) will be
495 saved into REDCap, a password-protected database. To assure the accuracy of data entry, data
496 will be verified in real-time by study staff via database-incorporated data entry checks. Data
497 output will be stored on a network devoted solely to the research activities associated with
498 MSU's Biomedical Research Informatics Core (BRIC). Electronic data stored on MSU's
499 network is backed up nightly by BRIC. Only the PI and designated members of her team will
500 have access to the final trial dataset. We expect to publish the results and share them on the
501 ClinicalTrials.gov database.

502 The High-Performance Computing Center (HPCC) will be used for checking, storing,
503 and analyzing MRI data. The HPCC is maintained by MSU's Institute for Cyber-Enabled
504 Research (ICER). The MRI data will also be stored on a secure server, backed up nightly, and
505 will only be accessible to study staff.

506 While all efforts will be made to minimize missing data through the use of electronic data
507 capture and real-time adherence data collection, missing data is still inevitable in RCTs. Thus,
508 we will employ several strategies to handle missing data with specific attention on how to handle
509 missing not-at-random data. Specifically, missing data will be handled via ML estimation with
510 auxiliary correlate inclusion [56, 57]. Missing not at random will be addressed with mixture
511 MNAR methods [58-60].

512 2.8 Statistical Analysis Plan

513 Primary and secondary outcome measures are obtained from neuroimaging data. The
514 brain regions selected have been shown in prior literature to be related to chronic pain [1, 61] and
515 respond to psychological interventions for the management of chronic pain conditions [62].

516 The 3D T1-weighted MPRAGE images will be segmented via FreeSurfer “recon-all”
517 [25]. The segmentation will be used in rs-fMRI functional connectivity and CBF analyses.

518 For rs-fMRI data analysis, image pre-processing and data analysis will be accomplished
519 by Analysis of Functional Neuroimages (AFNI) [63] and FreeSurfer [25] softwares. Signal time
520 course spikes will be detected and removed. Data points with excessive motion will be identified
521 (normalized motion derivative > 0.5 or vox outliers $> 10\%$) and modeled as regressors in
522 subsequent processing. Acquisition timing differences across slice locations will be corrected.
523 Rigid-body motion correction will be applied in three translational and three rotational
524 directions. Translational and rotational estimates, as well as their derivatives, will be modeled as
525 regressors for the subsequent noise regression step. For each subject, spatial blurring with a full-
526 width half-maximum of 4mm will be used to reduce random noise. CSF and white matter mean
527 signals will be modeled as nuisance variables. A band-pass filter (0.009 Hz-0.08 Hz) will be
528 applied. For the time course at each voxel location, temporal noise discussed above will be
529 removed via “3dDeconvolve” feature in AFNI [63].

530 **Functional Connectivity Analysis:** Each functional connectivity map will be warped to
531 the standard MNI152 space via AFNI. Correlation coefficients for each subject will be
532 transformed using Fisher’s Z. In the overall group analysis on the effect of WL-SPT, paired t-
533 tests between the pre and post WL-SPT functional connectivity maps will be conducted.
534 ANOVAs will be conducted on the functional connectivity differences between the ADAPT

535 completers and those in the waitlist condition. Statistically significant regions will be identified
536 based on $p < 0.05$ after multiple comparison correction, which will be estimated according to
537 Monte Carlo simulations in AFNI [63]. Changes between the amygdala and other network
538 regions (e.g., thalamus) that are implicated in pain processing are expected following ADAPT
539 versus waitlist (both following WL-SPT, and while at rest).

540 **Regional CBF analyses:** The relative CBF maps will be generated for each PASL scan.
541 We will use a whole-brain search to identify areas associated with connectivity with the
542 amygdala. The CBF maps will be aligned to the T1 MPRAGE. The mean CBF values on the
543 regions segmented by FreeSurfer (Fischl, 2012) will be calculated. The percentage change at
544 each region due to WL-SPT will be calculated. ANOVAs testing the percentage change of CBF
545 at the brain regions will be completed to compare the ADAPT completers to those in the waitlist
546 condition.

547 Pain-related brain CBF is expected to diminish for those that complete ADAPT compared
548 to the waitlist condition (Aim 2) following the WL-SPT and while at rest.

549 **Exploratory Analyses:** Neural mechanisms associated with a positive treatment
550 response (decreased pain intensity, unpleasantness, and state anxiety (after the WL-SPT and
551 while at rest) after ADAPT will be identified. Normalization of abnormal connectivity patterns
552 are predicted to categorize changes in participant-reported pain and anxiety. Specifically,
553 decreases in brain CBF and reductions in functional connectivity will be examined in relation to
554 improvements in pain and anxiety post treatment using multiple (linear) regression.

555 Given that other factors such as pubertal status and subjective pain levels could influence
556 the outcome, these factors will be included in the analysis as control covariates. Each

557 participant's exact age will be recorded at assessment allowing personnel to control for age as an
558 additional covariate should the need become apparent during preliminary analyses.

559 Network-based exploratory connectivity analysis will also be conducted. The cortical
560 nodes of the 17 networks identified by Yeo and colleagues (2011) will be identified via
561 Freesurfer segmentation (Fischl, 2012). Correlation between each pair of nodes in each network
562 will be calculated in MATLAB [64]. The connectivity within each network is the average of the
563 correlations of all pairs of nodes within a network. In assessing whole-brain connectivity, the
564 global average of the absolute r values between all nodes will be taken (to account for networks
565 known to be anticorrelated).

566 All correlation coefficients of each subject will be transformed using Fisher's Z using
567 SPSS (IBM SPSS Statistics for Windows, Version 26.0). In the overall group analysis on the
568 effect of WL-SPT, paired t -tests between the pre and post WL-SPT functional connectivity of
569 each network and global connectivity will be conducted. ANOVAs will be conducted to
570 investigate functional connectivity differences between the ADAPT completers and those in the
571 waitlist condition.

572 *2.8.1. Sample size and randomization specifications*

573 We used the following tool (<http://neuropowertools.org/neuropower/neuropowerinput/>) to
574 conduct sample size calculations for the rs-fMRI portion of the study. Power calculations were
575 based on prior studies by research members on functional connectivity data 1) pre and post
576 psychological therapy for pediatric pain (migraine) [65], and 2) comparing individuals with
577 pediatric pain (migraine) to healthy controls [66].

578 For within group changes, we relied on the pre/post data following a psychological
579 therapy for pediatric pain (migraine) [65]. A total sample size of 34 is required for power of .8
580 and $p < 0.05$ to observe at least moderate (e.g. mean effect size difference of 0.4 or greater)
581 effects. For between group changes, we utilized data comparing youth with chronic pain
582 (migraine) to healthy controls [66]. Based on these data, a total of 35 subjects are required for
583 power of .8 and $p < 0.05$.

584 *2.9 Interim analyses and stopping rules*

585 There are no planned interim analyses. Dr. Barber Garcia will assess adherence and
586 retention. If the treatment is deemed to be ineffective, unsafe, futile, or if there is evidence of
587 poor study performance (e.g., slow accrual, high losses-to-follow-up, and poor quality control), a
588 safety review may be warranted. This action would occur in consultation with the study mentors
589 (Zhu, Arnetz), the IMC, and NCCIH.

590 **Discussion**

591 FAPD are a set of common and chronic abdominal pain conditions [20, 21, 67] generally
592 categorized by hyperconnectivity between the amygdala and other regions of the brain
593 implicated in cognition and pain- processing [1, 61, 68, 69]. Further, FAPD are associated with
594 significant psychosocial impairment and may persist for a subset of youth [70, 71]. Pain-related
595 outcomes of FAPD are worse in the presence of comorbid anxiety [5, 72]. Further, anxiety, in
596 combination with clinically elevated levels of pain and pain-related disability, are associated
597 with persistent functional impairment [8]. Anxiety also diminishes impact of pain-focused CBT
598 [9], which is among the most widely researched approach to care for pediatric chronic pain
599 conditions [73]. Fortunately, a coping skills program called the Aim to Decrease Anxiety and
600 Pain Treatment (ADAPT) has been developed [10] that addresses comorbid anxiety and chronic

601 pain symptoms for youth with FAPD. The program consists of a blend of CBT strategies and
602 was infused with mindfulness meditation to be delivered by a trained interventionist weekly for a
603 period of six weeks [10, 14]. ADAPT has shown to be superior to improving pain-related
604 disability and anxiety as compared to standard care in a randomized clinical trial [14]. However,
605 the potential neural mechanisms underlying the effect of this treatment are unknown. Once such
606 factors are investigated through our neuromechanistic trial, we will have an enhanced
607 understanding of mechanisms underlying treatment response to psychological interventions
608 addressing pain and comorbid anxiety.

609 Our trial utilizes a validated visceral symptom provocation task, the water loading
610 symptom provocation task (WL-SPT) [37]. We have intentionally used this task during
611 neuroimaging the brains of youth with FAPD [1], who otherwise may or may not be
612 experiencing an active pain flare at the time of imaging. The WL-SPT is known to induce
613 sensations including pain intensity and pain unpleasantness similar to, but less severe than, an
614 active pain flare [37]. Therefore, in our current neuromechanistic trial, we will compare youth
615 functional connectivity between the amygdala and other regions of the brain after ADAPT versus
616 waitlist during after the WL-SPT, in addition to rest. To enhance the rigor of the results, visual
617 analog measures of pain severity/unpleasantness [32, 33] and anxiety [36] will be obtained
618 throughout the scanning. Such a research design employing a validated visceral symptom
619 provocation task has the potential to advance the literature.

620 We expect minimal risk and potential benefits to participants and their families following
621 receipt of the ADAPT program, which is an evidence-based program to improve pain-related
622 disability and anxiety in youth with FAPD [14]. Limitations of the current study design include
623 lack of active treatment comparator and a relatively modest sample size. We also recognize

624 functional connectivity is based on surrogates of neural activity (i.e., changes in blood flow in
625 response to neural activity); thus, findings should be interpreted within that lens. Future planned
626 research includes dissemination and implementation trials, examining sustainability of treatment
627 effects and associated neural mechanisms, and investigating neural mechanisms underlying
628 components of treatment response, similar to work currently underway in pediatric migraine
629 [65].

630 Given that FAPD are common [2] and costly [74] conditions associated with changes in
631 neural processing [1], and effective programs such as ADAPT are available [14], it is important
632 to understanding neural mechanisms of treatment response. This is particularly true in the
633 adolescent population as FAPD [5, 8] and anxiety [75] increases and can become more severe as
634 children age and transition to adolescence. This is a period marked by pubertal and
635 developmental changes that may alter changes in neural functioning associated with pain
636 processing [76]. Therefore, additional investigation of the impact of pubertal status on pain
637 processing following effective treatments will be important in future research. Though this work
638 is specific to FAPD, findings may be a guide to enhance the understanding of treatment response
639 of other pediatric chronic pain conditions (which are also generally categorized by enhanced
640 functional connectivity between the amygdala and other regions associated with pain) [77, 78].
641 This is critically important as chronic pain conditions are the most common childhood chronic
642 illnesses and most expensive health problem facing children in the US [79].

643 **Conclusion**

644 In conclusion, this is the first neuromechanistic RCT of a tailored psychological treatment to
645 target pain and anxiety in youth with FAPD. Results aim to improve understanding of
646 mechanisms underlying response to psychological treatments for FAPD.

647
648
649
650
651
652
653
654
655
656
657

658

659

660

661

662

663

664

665

666

667

Acknowledgements

We thank the gastroenterology team at Helen DeVos Children’s Hospital including Drs. Vanessa Cardenas-Soto, Peter Freswick, Deborah Cloney, Sarah Henkel, Amie Hinshaw, nurse practitioner Ashley Verhey, and social workers Mackenzie Mullins and Jamie Bart for supporting the recruitment efforts and execution of the study. We thank Drs. Amy Pugh, Alexander Redman, Christina Varghese, and Leo Fawaz for providing on-call services. We thank Mallet Reid and Sukhesh Sudan for their assistance with randomization. We thank Emme Bourassa, Kara Nearanz, and Caitlin Wilterink for their support as Corewell Health research assistants. We thank Elise Cheney-Makens for her support with recruitment. We thank Robert Jones, Stacy Clegg, Becky Ruitter, Carrie Popilek, Michele Harvey, Steven Zomberg, and Crista Bradley for their support as MRI technologists on the project.

668 **References**

- 669 1. Cunningham NR, Nahman-Averbuch H, Lee GR, King CD, Coghill RC. Amygdalar
670 functional connectivity during resting and evoked pain in youth with functional abdominal pain
671 disorders. *J Pain*. 2022;163(10):2031-43.
- 672 2. King S, Chambers CT, Huguet A, MacNevin RC, McGrath PJ, Parker L, et al. The
673 epidemiology of chronic pain in children and adolescents revisited: a systematic review. *J Pain*.
674 2011;152(12):2729-38.
- 675 3. Walker LS, Sherman AL, Bruehl S, Garber J, Smith CA. Functional abdominal pain patient
676 subtypes in childhood predict functional gastrointestinal disorders with chronic pain and
677 psychiatric comorbidities in adolescence and adulthood. *J Pain*. 2012;153(9):1798-806.
- 678 4. Størdal K, Nygaard EA, Bentsen BS. Recurrent abdominal pain: a five-year follow-up
679 study. *Acta Paediatr*. 2005;94(2):234-6.
- 680 5. Cunningham NR, Cohen MB, Farrell MK, Mezzoff AG, Lynch-Jordan A, Kashikar-Zuck
681 S. Concordant parent-child reports of anxiety predict impairment in youth with functional
682 abdominal pain. *J Pediatr Gastroenterol Nutr*. 2014;60(3):312-7.
- 683 6. Dorn LD, Campo JC, Thato S, Dahl RE, Lewin D, Chandra R, et al. Psychological
684 comorbidity and stress reactivity in children and adolescents with recurrent abdominal pain and
685 anxiety disorders. *J Am Acad Child Adolesc Psychiatry*. 2003;42(1):66-75.
- 686 7. Dufton LM, Dunn MJ, Compas BE. Anxiety and somatic complaints in children with
687 recurrent abdominal pain and anxiety disorders. *J Pediatr Psychol*. 2009;34(2):176-86.
- 688 8. Cunningham NR, Jagpal A, Peugh J, Cohen MB, Farrell MK, Mezzoff AG, et al. Using a
689 simple risk categorization to predict outcomes in pediatric functional abdominal pain at 6 months
690 *J Pediatr Gastroenterol Nutr*. 2017;64(5):685-90.
- 691 9. Cunningham NR, Jagpal A, Tran ST, Kashikar-Zuck S, Goldschneider KR, Coghill RC, et
692 al. Anxiety Adversely Impacts Response to Cognitive Behavioral Therapy in Children with
693 Chronic Pain. *J Pediatr*. 2016;171:227-33.
- 694 10. Cunningham NR, Nelson S, Jagpal A, Moorman E, Farrell M, Pentiuk S, et al.
695 Development of the Aim to Decrease Anxiety and Pain Treatment for Pediatric Functional
696 Abdominal Pain Disorders. *J Pediatr Gastroenterol Nutr*. 2018;66(1):16-20.
- 697 11. Lyneham HJ, Abbott MJ, Wignall A, Rapee RA. The Cool Kids Anxiety Treatment
698 Program. 2003.
- 699 12. Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive
700 behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind,
701 randomized, controlled clinical trial. *Arthritis Rheum*. 2012;64(1):297-305.
- 702 13. Broderick P. *Learning to breathe*. Oakland, CA: New Harbinger Publications; 2013.
- 703 14. Cunningham NR, Kalomiris A, Peugh J, Farrell M, Pentiuk S, Mallon D, et al. Cognitive
704 Behavior Therapy Tailored to Anxiety Symptoms Improves Pediatric Functional Abdominal Pain
705 Outcomes: A Randomized Clinical Trial. *J Pediatr*. 2021;230:62-70.e3.
- 706 15. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default
707 mode of brain function. *Proceedings of the national academy of sciences*. 2001;98(2):676-82.
- 708 16. Baliki MN, Chialvo DR, Geha PY, Levy RM, Harden RN, Parrish TB, et al. Chronic pain
709 and the emotional brain: specific brain activity associated with spontaneous fluctuations of
710 intensity of chronic back pain. *J Neurosci*. 2006;26(47):12165-73.
- 711 17. Baliki MN, Geha PY, Apkarian AV, Chialvo DR. Beyond feeling: chronic pain hurts the
712 brain, disrupting the default-mode network dynamics. *J Neurosci*. 2008;28(6):1398-403.

- 713 18. Cunningham NR, Kashikar-Zuck S, Coghill RC. Brain mechanisms impacted by
714 psychological therapies for pain: identifying targets for optimization of treatment effects. *PAIN*
715 *Reports*. 2019;4(4):e767.
- 716 19. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized
717 anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-7.
- 718 20. Walker LS, Lipani TA, Greene JW, Caines K, Stutts J, Polk DB, et al. Recurrent abdominal
719 pain: symptom subtypes based on the Rome II Criteria for pediatric functional gastrointestinal
720 disorders. *J Pediatr Gastroenterol Nutr*. 2004;38(2):187-91.
- 721 21. Koppen IJ, Nurko S, Saps M, Di Lorenzo C, Benninga MA. The pediatric Rome IV criteria:
722 what's new? *Expert Rev Gastroenterol Hepatol*. 2017;11(3):193-201.
- 723 22. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
724 measure. *J Gen Intern Med*. 2001;16(9):606-13.
- 725 23. Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety
726 and depression: the PHQ-4. *Psychosomatics*. 2009;50(6):613-21.
- 727 24. Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The
728 organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J*
729 *Neurophysiol*. 2011;106(3):1125-65.
- 730 25. Fischl B. *FreeSurfer*. *Neuroimage*. 2012;62(2):774-81.
- 731 26. Birn RM, Molloy EK, Patriat R, Parker T, Meier TB, Kirk GR, et al. The effect of scan
732 length on the reliability of resting-state fMRI connectivity estimates. *Neuroimage*. 2013;83:550-
733 8.
- 734 27. Fernandez Z, Scheel N, Baker JH, Zhu DC. Functional connectivity of cortical resting-state
735 networks is differentially affected by rest conditions. *Brain Res*. 2022;1796:148081.
- 736 28. Chang SE, Zhu DC. Neural network connectivity differences in children who stutter. *Brain*.
737 2013;136(Pt 12):3709-26.
- 738 29. Cox RW. AFNI: what a long strange trip it's been. *Neuroimage*. 2012;62(2):743-7.
- 739 30. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive
740 alternating inversion recovery (FAIR) technique: application to functional mapping. *Magn Reson*
741 *Med*. 1995;34(3):293-301.
- 742 31. Wong EC, Buxton RB, Frank LR. Quantitative imaging of perfusion using a single
743 subtraction (QUIPSS and QUIPSS II). *Magn Reson Med*. 1998;39(5):702-8.
- 744 32. McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, et al. Core
745 outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials:
746 PedIMMPACT recommendations. *J Pain*. 2008;9(9):771-83.
- 747 33. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement
748 characteristics of mechanical visual analogue and simple numerical rating scales. *J Pain*.
749 1994;56(2):217-26.
- 750 34. Palermo TM, Eccleston C, Lewandowski AS, Williams ACdC, Morley S. Randomized
751 controlled trials of psychological therapies for management of chronic pain in children and
752 adolescents: an updated meta-analytic review. *J Pain*. 2010;148(3):387-97.
- 753 35. Zeidan F, Martucci KT, Kraft RA, Gordon NS, McHaffie JG, Coghill RC. Brain
754 mechanisms supporting the modulation of pain by mindfulness meditation. *J Neurosci*.
755 2011;31(14):5540-8.
- 756 36. Kindler CH, Harms C, Amsler F, Ihde-Scholl T, Scheidegger D. The visual analog scale
757 allows effective measurement of preoperative anxiety and detection of patients' anesthetic
758 concerns. *Anesth Analg*. 2000;90(3):706-12.

- 759 37. Walker LS, Williams SE, Smith CA, Garber J, Van Slyke DA, Lipani T, et al. Validation
760 of a symptom provocation test for laboratory studies of abdominal pain and discomfort in children
761 and adolescents. *J Pediatr Psychol*. 2006;31(7):703-13.
- 762 38. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory.
763 *Neuropsychologia*. 1971;9(1):97-113.
- 764 39. Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status:
765 Reliability, validity, and initial norms. *J Youth Adolesc*. 1988;17(2):117-33.
- 766 40. Mossman SA, Luft MJ, Schroeder HK, Varney ST, Fleck DE, Barzman DH, et al. The
767 Generalized Anxiety Disorder 7-item scale in adolescents with generalized anxiety disorder:
768 Signal detection and validation. *Ann Clin Psychiatry*. 2017;29(4):227-34a.
- 769 41. Albano A, Silverman W. The Anxiety Disorders Interview Schedule for Children for DSM-
770 IV: Clinician manual (child and parent versions). San Antonio, TX: Psychological Corporation.
771 1996;183:649-56.
- 772 42. Walker LS, Greene JW. The functional disability inventory: measuring a neglected
773 dimension of child health status. *J Pediatr Psychol*. 1991;16(1):39-58.
- 774 43. Kashikar-Zuck S, Flowers S, Claar R, Guite J, Logan D, Lynch-Jordan A, et al. Clinical
775 utility and validity of the Functional Disability Inventory among a multicenter sample of youth
776 with chronic pain. *J Pain*. 2011;152(7):1600-7.
- 777 44. Varni JW, Stucky BD, Thissen D, DeWitt EM, Irwin DE, Lai J-S, et al. PROMIS Pediatric
778 Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. *J Pain*.
779 2010;11(11):1109-19.
- 780 45. Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, et al. The Screen for
781 Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric
782 characteristics. *J Am Acad Child Adolesc Psychiatry*. 1997;36(4):545-53.
- 783 46. Mental Health Screening and Assessment Tools for Primary Care. 2010. In: *Addressing*
784 *Mental Health Concerns in Primary Care* [Internet]. Am Acad Pediatr
- 785 47. Birmaher B, Brent D, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric
786 properties of the Screen for Anxiety Related Emotional Disorders (SCARED): A replication study.
787 *J Am Acad Child Adolesc Psychiatry*. 1999;38(10):1230-6.
- 788 48. Mano KEJ, Evans JR, Tran ST, Khan KA, Weisman SJ, Hainsworth KR. The psychometric
789 properties of the Screen for Child Anxiety Related Emotional Disorders in pediatric chronic pain.
790 *J Pediatr Psychol*. 2012;37(9):999-1011.
- 791 49. COVID-19 Exposure and Family Impact Survey (CEFIS). 2020.
- 792 50. Bursch B, Tsao JC, Meldrum M, Zeltzer LK. Preliminary validation of a self-efficacy scale
793 for child functioning despite chronic pain (child and parent versions). *J Pain*. 2006;125(1):35-42.
- 794 51. Crombez G, Bijttebier P, Eccleston C, Mascagni T, Mertens G, Goubert L, et al. The child
795 version of the pain catastrophizing scale (PCS-C): a preliminary validation. *J Pain*.
796 2003;104(3):639-46.
- 797 52. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales
798 (DASS-21): Construct validity and normative data in a large non-clinical sample. *Br J Clin*
799 *Psychol*. 2005;44(2):227-39.
- 800 53. Bethell CD, Carle A, Hudziak J, Gombojav N, Powers K, Wade R, et al. Methods to assess
801 adverse childhood experiences of children and families: toward approaches to promote child well-
802 being in policy and practice. *Acad Pediatr*. 2017;17(7):S51-S69.

- 803 54. Miller AK, Ely SL, Barber Garcia BN, Richardson P, Cunningham NR. Engagement
804 during a Mixed In-Person and Remotely Delivered Psychological Intervention for Youth with
805 Functional Abdominal Pain Disorders and Anxiety. *Children (Basel)*. 2021;8(9).
- 806 55. Kalomiris AE, Ely SL, Love SC, Mara CA, Cunningham NR. Child-Focused Cognitive
807 Behavioral Therapy for Pediatric Abdominal Pain Disorders Reduces Caregiver Anxiety in
808 Randomized Clinical Trial. *J Pain*. 2022;23(5):810-21.
- 809 56. Graham JW. Adding Missing-Data-Relevant Variables to FIML-Based Structural Equation
810 Models. *Struct Equ Modeling*. 2003;10(1):80-100.
- 811 57. Enders C. *Applied Missing Data Analysis*. The Guilford Press 2010.
- 812 58. Gottfredson NC, Bauer DJ, Baldwin SA. Modeling Change in the Presence of Non-
813 Randomly Missing Data: Evaluating A Shared Parameter Mixture Model. *Struct Equ Modeling*.
814 2014;21(2):196-209.
- 815 59. Muthén B, Asparouhov T, Hunter AM, Leuchter AF. Growth modeling with nonignorable
816 dropout: alternative analyses of the STAR*D antidepressant trial. *Psychol Methods*.
817 2011;16(1):17-33.
- 818 60. Sterba SK, Gottfredson NC. Diagnosing global case influence on MAR versus MNAR
819 model comparisons. *Struct Equ Modeling*. 2015;22(2):294-307.
- 820 61. Simons LE, Moulton EA, Linnman C, Carpino E, Becerra L, Borsook D. The human
821 amygdala and pain: evidence from neuroimaging. *Hum Brain Mapp*. 2014;35(2):527-38.
- 822 62. Simons LE, Pielech M, Erpelding N, Linnman C, Moulton E, Sava S, et al. The responsive
823 amygdala: treatment-induced alterations in functional connectivity in pediatric complex regional
824 pain syndrome. *J Pain*. 2014;15(9):1727-42.
- 825 63. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance
826 neuroimages. *Comput Biomed Res*. 1996;29(3):162-73.
- 827 64. MATLAB 9.13.0 (R2022b) ed. Natick, Massachusetts: The MathWorks Inc.; 2022.
- 828 65. Nahman-Averbuch H, Schneider VJ, 2nd, Chamberlin LA, Kroon Van Diest AM, Peugh
829 JL, Lee GR, et al. Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine
830 in Children and Adolescents. *Headache*. 2020;60(6):1165-82.
- 831 66. Nahman-Averbuch H, Leon E, Hunter BM, Ding L, Hershey AD, Powers SW, et al.
832 Increased pain sensitivity but normal pain modulation in adolescents with migraine. *J Pain*.
833 2019;160(5):1019-28.
- 834 67. Walker LS, Lipani TA, Greene JW, Caines K, Stutts J, Polk DB, et al. Recurrent abdominal
835 pain: symptom subtypes based on the Rome II criteria for pediatric functional gastrointestinal
836 disorders. *J Pediatr Gastroenterol Nutr*. 2004;38(2):187-91.
- 837 68. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions
838 activated during rectal distension in irritable bowel syndrome. *J Gastroenterol*. 2011;140(1):91-
839 100.
- 840 69. Liu X, Silverman A, Kern M, Ward BD, Li SJ, Shaker R, et al. Excessive coupling of the
841 salience network with intrinsic neurocognitive brain networks during rectal distension in
842 adolescents with irritable bowel syndrome: a preliminary report. *Neurogastroenterol Motil*.
843 2016;28(1):43-53.
- 844 70. Walker LS, Guite JW, Duke M, Barnard JA, Greene JW. Recurrent abdominal pain: A
845 potential precursor of irritable bowel syndrome in adolescents and young adults. *J Pediatr*.
846 1998;132(6):1010-5.

- 847 71. Ramchandani PG, Fazel M, Stein A, Wiles N, Hotopf M. The impact of recurrent
848 abdominal pain: predictors of outcome in a large population cohort. *Acta Paediatr.*
849 2007;96(5):697-701.
- 850 72. Stanford EA, Chambers CT, Biesanz JC, Chen E. The frequency, trajectories and predictors
851 of adolescent recurrent pain: A population-based approach. *J Pain.* 2008;138(1):11-21.
- 852 73. Fisher E, Villanueva G, Henschke N, Nevitt SJ, Zempsky W, Probyn K, et al. Efficacy and
853 safety of pharmacological, physical, and psychological interventions for the management of
854 chronic pain in children: a WHO systematic review and meta-analysis. *J Pain.* 2022;163(1):e1-
855 e19.
- 856 74. Dhroove G, Chogle A, Saps M. A Million-dollar Work-up for Abdominal Pain: Is It Worth
857 It? *J Pediatr Gastroenterol Nutr.* 2010;51(5):579-83 10.1097/MPG.0b013e3181de0639.
- 858 75. APA. Diagnostic and statistical manual of mental disorders (5th ed). Arlington, VA: Am
859 Psychiatr Publ; 2013.
- 860 76. Nahman-Averbuch H, Li R, Boerner KE, Lewis C, Garwood S, Palermo TM, et al.
861 Alterations in pain during adolescence and puberty. *Trends Neurosci.* 2023;46(4):307-17.
- 862 77. Simons LE, Moulton EA, Linnman C, Carpino E, Becerra L, Borsook D. The human
863 amygdala and pain: evidence from neuroimaging. *Hum Brain Mapp.* 2014;35(2):527-38.
- 864 78. Erpelding N, Simons L, Lebel A, Serrano P, Pielech M, Prabhu S, et al. Rapid treatment-
865 induced brain changes in pediatric CRPS. *Brain Struct Funct.* 2016;221(2):1095-111.
- 866 79. Groenewald CB, Essner BS, Wright D, Fesinmeyer MD, Palermo TM. The Economic
867 Costs of Chronic Pain Among a Cohort of Treatment-Seeking Adolescents in the United States. *J*
868 *Pain.* 2014;15(9):925-33.
- 869

	STUDY PERIOD			
	Enrollment	Baseline	Randomization	Post Assessment
TIMEPOINT	$-t_1$	t_1		t_2
ENROLLMENT:				
Eligibility screen	X			
Informed consent	X			
Allocation			X	
CONDITIONS:				
<i>ADAPT*</i>			X	
<i>Waitlist</i>			X	
ASSESSMENTS:				
<i>fMRI</i>		X		X
<i>Pain and anxiety ratings</i>		X		X
<i>Other study surveys</i>	X	X		X

*Aim to Decrease Anxiety and Pain Treatment (ADAPT)

Figure 1

Identification

Helen DeVos Children's Hospital Outpatient Clinics

A gastroenterology provider (physician or nurse practitioner) will confirm identification of eligible patients based on functional abdominal pain disorder (FAPD) diagnosis. The GI team will introduce the study to patients.



Consent

In-person at patients' clinic visit or via phone

A research assistant will obtain consent from interested patients in clinic or thereafter via phone.

medRxiv preprint doi: <https://doi.org/10.1101/2024.02.08.24302498>; this version posted February 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Clinic screening

In-person at patients' clinic visit or via phone

Further study eligibility measures (e.g., measures of anxiety) will be obtained either from the medical record or by study team. The research assistant will also assess MRI compatibility (e.g., claustrophobia screening and MRI safety screening) at patients' clinic visit or via phone/REDCap.

The patient will be queried for their current participation in psychological therapy for pain or anxiety.




Neuroimaging screening

Participants' MRI visits will be scheduled

Baseline scans will be reviewed by radiologists for abnormalities prior to enrollment and randomization.

Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.08.24302498>; this version posted February 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3




Figure 4